Theravance Biopharma Inc - Company Profile
Powered by 
All the data and insights you need on Theravance Biopharma Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Theravance Biopharma Inc Strategy Report
- Understand Theravance Biopharma Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Theravance Biopharma Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Theravance Biopharma Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 20 Sep 2021 | Lorem |
| Theravance’s Phase III ampreloxetine trial needs dramatic improvement in neurogenic orthostatic hypotension despite a positive shot at trial success, experts say | 01 Apr 2021 | Reynald Castaneda |
| Theravance’s 188-patient Phase III ampreloxetine trial in neurogenic orthostatic hypotension very close to recruitment completion; IQVIA is CRO, investigator says | 18 Mar 2021 | Reynald Castaneda |
| Incyte, Lilly may have JAK inhibitor mechanistic edge over Pfizer for COVID-19; Theravance candidate may be limited by nebulised approach, experts say | 28 Apr 2020 | Reynald Castaneda;Manasi Vaidya |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer